BC Innovations | Dec 12, 2019
Tools & Techniques

New hepatic stellate cell subset drives liver fibrosis

A team including University of Edinburgh and Gilead researchers has used single-cell sequencing to zero in on a pathogenic subpopulation of hepatic stellate cells that could be targeted to treat liver fibrosis. Reported in a...
BioCentury | Apr 30, 2019

Why liver disease newco Alentis is aiming for one of largest Swiss A rounds

Liver disease newco Alentis Therapeutics is starting off small with the first close of its series A round, but the additional capital it expects to raise over the next six months could give it the...
BC Week In Review | Sep 13, 2018
Clinical News

BMS's IPF therapy discontinued after Phase II safety signal

Data published in Chest showed that a twice-daily 600 mg dose of BMS-986020 from Bristol-Myers Squibb Co. (NYSE:BMY) significantly slowed the rate of decline in forced vital capacity (FVC) vs. placebo in the Phase II...
Items per page:
1 - 3 of 3